Purpose: Apremilast, an oral phosphodiesterase 4 inhibitor, was effective in clinical trials in
patients with moderate plaque psoriasis (affected body surface area [BSA] 5% to 10%) …

Background: Apremilast is a new oral drug for the treatment of moderate to severe plaque
psoriasis that reduces inflammation by inhibiting phosphodiesterase 4. Its efficacy and safety …

Background: Apremilast is an oral phosphodiesterase 4 (PDE4) inhibitor used for the
treatment of moderate to severe psoriasis. Long-term data on the effectiveness and drug …

BACKGROUND: Many patients with moderate plaque psoriasis are undertreated despite
broadening treatment options. In the phase IV UNVEIL study, oral apremilast demonstrated …

Background Randomized, controlled trials demonstrated efficacy and safety of apremilast for
moderate-to-severe plaque psoriasis and psoriatic arthritis. Objective Assess long-term …

Abstract Introduction and Objectives: Patients (pts) with moderate plaque psoriasis are often
inadequately treated (Armstrong, 2013), and there remains an unmet medical need for an …

Background: Clinical trial data have shown apremilast, an oral phosphodiesterase-4
inhibitor, to be efficacious and safe for the treatment of psoriasis. However, little real-world …

Background Little has been published on the real‐world effectiveness and safety of
apremilast in psoriasis. Objectives To evaluate the effectiveness, safety and drug survival of …

Background/Objective: Patients with moderate plaque psoriasis (ie, 5–10% psoriasis-
involved Body Surface Area [BSA]) often receive no treatment or are undertreated with …

Apremilast is a phosphodiesterase-4 inhibitor taken orally. Little information about its use in
routine clinical practice is available. We aimed to assess treatment safety and persistence …